Last reviewed · How we verify
NCT07385599
FIM Study of the LAmbre™ II LAA Occluder in Non-Valvular AF Patients
NA trial testing LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System in Non-valvular Atrial Fibrillation (NVAF) in 10 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2027
Quick facts
| Lead sponsor | Lifetech Scientific (Shenzhen) Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 10 |
| Start date | 19 January 2026 |
| Primary completion | 31 December 2027 |
| Estimated completion | 1 March 2028 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- LAmbre™ II Left Atrial Appendage Occluder and Occluder Delivery System
Conditions studied
- Non-valvular Atrial Fibrillation (NVAF) — all drugs for Non-valvular Atrial Fibrillation (NVAF) →
Sponsor
Lifetech Scientific (Shenzhen) Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Non-valvular Atrial Fibrillation (NVAF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the preliminary safety and feasibility of the LAmbreTM II Left Atrial Appendage Occluder and the Occluder Delivery System in patients with non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07385599
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-valvular Atrial Fibrillation (NVAF)
Currently open trials in the same condition.
- NCT06725355 — To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adul · Phase 1 · active not recruiting
Other Lifetech Scientific (Shenzhen) Co., Ltd. trials
Trials by the same sponsor.
- NCT06915545 — Study on the Aortic Arch Single Branch Stent Graft System · NA · recruiting
- NCT06849635 — Cera™ ASD Occluder Post-Market Clinical Follow-Up Study · recruiting
- NCT06700174 — Lifetech AcuMark™ Sizing Balloon Post-Market Clinical Follow-up Study · recruiting
- NCT06520774 — Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases · NA · recruiting
- NCT05893758 — Lifetech Cera™ PFO Occluder Post-Market Clinical Follow-Up · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07385599 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lifetech Scientific (Shenzhen) Co., Ltd.
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07385599.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing